The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy

Stephen L. Curry, Judith Rine, Charles W. Whitney, William A. Nahhas, Rodrique Mortel, Laurence Demers

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Ten patients had serial evaluations of plasma prostaglandin E2, prostaglandin , and 6-keto-PG during administration of cis-platinum chemotherapy. No significant changes were noted in PGF and 6-keto-PGF whereas PGE2 showed a decrease. This would indicate that the nausea and vomiting of platinum therapy is not a result of tumor release of prostaglandins. All patients had known residual cancer and all had elevated levels of PGE2 and 6-keto-PGF.

Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalGynecologic Oncology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1981

Fingerprint

Dinoprostone
Nausea
Cisplatin
Prostaglandins
Vomiting
Dinoprost
Residual Neoplasm
Platinum
Therapeutics
Drug Therapy
Neoplasms
prostaglandin F1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Curry, Stephen L. ; Rine, Judith ; Whitney, Charles W. ; Nahhas, William A. ; Mortel, Rodrique ; Demers, Laurence. / The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy. In: Gynecologic Oncology. 1981 ; Vol. 12, No. 1. pp. 89-91.
@article{5f4c3170fc83431796b3422be113ffaf,
title = "The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy",
abstract = "Ten patients had serial evaluations of plasma prostaglandin E2, prostaglandin 2α, and 6-keto-PG1α during administration of cis-platinum chemotherapy. No significant changes were noted in PGF2α and 6-keto-PGF1α whereas PGE2 showed a decrease. This would indicate that the nausea and vomiting of platinum therapy is not a result of tumor release of prostaglandins. All patients had known residual cancer and all had elevated levels of PGE2 and 6-keto-PGF1α.",
author = "Curry, {Stephen L.} and Judith Rine and Whitney, {Charles W.} and Nahhas, {William A.} and Rodrique Mortel and Laurence Demers",
year = "1981",
month = "1",
day = "1",
doi = "10.1016/0090-8258(81)90099-8",
language = "English (US)",
volume = "12",
pages = "89--91",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy. / Curry, Stephen L.; Rine, Judith; Whitney, Charles W.; Nahhas, William A.; Mortel, Rodrique; Demers, Laurence.

In: Gynecologic Oncology, Vol. 12, No. 1, 01.01.1981, p. 89-91.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy

AU - Curry, Stephen L.

AU - Rine, Judith

AU - Whitney, Charles W.

AU - Nahhas, William A.

AU - Mortel, Rodrique

AU - Demers, Laurence

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Ten patients had serial evaluations of plasma prostaglandin E2, prostaglandin 2α, and 6-keto-PG1α during administration of cis-platinum chemotherapy. No significant changes were noted in PGF2α and 6-keto-PGF1α whereas PGE2 showed a decrease. This would indicate that the nausea and vomiting of platinum therapy is not a result of tumor release of prostaglandins. All patients had known residual cancer and all had elevated levels of PGE2 and 6-keto-PGF1α.

AB - Ten patients had serial evaluations of plasma prostaglandin E2, prostaglandin 2α, and 6-keto-PG1α during administration of cis-platinum chemotherapy. No significant changes were noted in PGF2α and 6-keto-PGF1α whereas PGE2 showed a decrease. This would indicate that the nausea and vomiting of platinum therapy is not a result of tumor release of prostaglandins. All patients had known residual cancer and all had elevated levels of PGE2 and 6-keto-PGF1α.

UR - http://www.scopus.com/inward/record.url?scp=0019487842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019487842&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(81)90099-8

DO - 10.1016/0090-8258(81)90099-8

M3 - Review article

C2 - 7196862

AN - SCOPUS:0019487842

VL - 12

SP - 89

EP - 91

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -